Lilly’s New Combination Beats its Own Monotherapy
- The FDA granted full approval on 18 September 2026 to Eli Lilly‘s Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, detected by an FDA-authorised test, after progression on at least one line of endocrine therapy.
- In the Phase 3 EMBER-3 trial, median progression-free survival was 11.1 months on imlunestrant plus abemaciclib (n=67) against 5.5 months on imlunestrant alone (n=92), a hazard ratio of 0.53 (95% CI 0.35 to 0.80). Lilly describes the result as a doubling of median PFS.
- The FDA also approved the Guardant360 CDx assay as the companion diagnostic for identifying ESR1 mutations in this setting. Both products are all-oral, and Lilly states the combination requires no monitoring beyond what Verzenio already carries.
- This is the second Inluriyo approval inside 12 months. The drug was cleared as monotherapy in the same ESR1-mutated population in September 2025. Verzenio was first approved in 2017. The adjuvant study EMBER-4, with more than 8,000 patients, has initial results expected in 2027.
CI read
The control arm was Lilly’s own single agent. EMBER-3 answers whether adding Verzenio to Inluriyo helps. It does not answer what a payer or a formulary committee is actually choosing between.
- The trial compares the company with itself. A patient progressing after endocrine therapy is not choosing between imlunestrant and imlunestrant plus abemaciclib. They are choosing between an oral SERD plus a CDK4/6 inhibitor and the alternatives, including fulvestrant combinations and competing CDK4/6 agents. That comparison does not exist in the registration package, and every access negotiation will ask for it.
- A nine-year-old asset just acquired a biomarker-selected second life. Verzenio entered in 2017 and now sits inside a label that requires an FDA-authorised ESR1 test to reach. Combination approval of that kind converts a maturing brand into a component of a tested regimen, which is a far harder position to displace than a standalone CDK4/6 inhibitor.
- The constraint is the test, not the tablet. Eligibility runs through Guardant360 CDx, so the addressable population equals the number of patients who actually get sequenced at progression. With 159 patients across both arms of the pivotal subgroup, the commercial variable is testing rate, and that is a diagnostics execution problem rather than an oncology one.